Signal/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-re-scored-composite-v2.md

Signal CGM — Re-Scored Composite Model v2

Asset Sale Primary (50%) · Pilot Secondary (30%) · SaaS Tertiary (20%)

MA + Medicaid First Proof-of-Concept Payer Scope

STTIL Solutions LLC | April 2026

---

Priority Weights

Objective	Weight	Rationale
Asset sale / strategic handoff	50%	Fastest path to capital realization
Pilot validation	30%	Evidence from pilot raises asset sale price
SaaS ICP potential	20%	Informs asset buyer's deployment ROI

---

Scoring Assumption Audit

Asset Sale — Why These Weights

Distribution reach (30%): An asset sale to a platform touching 500+ suppliers is worth orders of magnitude more than one touching one. This is the dominant criterion because it determines the multiplier on the asset's downstream value.

Strategic need (25%): Pull motion (buyer has documented gap) is more reliable than push motion (we convince buyer they need it). NikoHealth's CGM intelligence gap is documented and real. Billing companies' MA plan-rule complexity is felt daily.

Price ceiling (20%): Current $25K–$60K is priced for a direct supplier buyer. A platform vendor or MSO can justify 3–5× that. Weight at 20% because price ceiling is contingent on strategic need — no need, no premium.

Speed to close (15%): Closing faster is better but not at the expense of deal size. Pursue fast-close candidates in parallel with long-cycle targets.

Build vs. buy (10%): Modifier on other criteria. Accelerates a deal that already has strategic need; doesn't create one where those are absent.

Pilot — Why These Weights

Data accessibility (25%): Pilot must generate measurable denial rate change. Requires structured CGM billing data with denial reason codes — not spreadsheets.

Cooperation likelihood (20%): Active partner engagement multiplies data access value. Poor data + high cooperation still generates useful qualitative signal.

Signal quality (20%): Pilot must generalize to the asset buyer's customer base. Single Florida supplier = anecdote. Billing company across 3 MACs = evidence.

PHI/compliance overhead (20%): High-overhead pilot = delayed pilot. Given CB 2028 window, compliance friction is a real timeline risk.

Feedback loop speed (15%): A 30–60 day feedback cycle is acceptable; 6 months is not viable given the urgency window.

---

Individual Segment Scores — MA + Medicaid Scope Applied

NikoHealth-Type Platform Vendor

Asset Sale Sub-Score:

Criterion	Wt	Score	Note
Distribution reach	30%	10	Serves exact buyer profile across hundreds of suppliers
Strategic need	25%	10 (+1)	MA+Medicaid scope widens the gap — no platform has plan-specific rules
Price ceiling	20%	9	MA module = 3–5× current ask to a motivated platform buyer
Speed to close	15%	3	Enterprise procurement: 4–8 months minimum
Build vs. buy	10%	8 (+1)	MA plan-rule maintenance is ongoing data work, not a sprint
Sub-score: 8.55

Pilot Sub-Score:

Criterion	Wt	Score	Note
Data accessibility	25%	10	Best dataset: all supplier clients across all payers
Cooperation likelihood	20%	3 (−1)	Exposing own platform gap is sensitive under MA scope
Signal quality	20%	10	Multi-supplier, multi-plan, multi-jurisdiction
PHI overhead	20%	7	HIPAA infrastructure exists
Feedback speed	15%	4	Enterprise review before data access
Sub-score: 7.10

SaaS ICP Score: 4.65 NikoHealth Composite: (8.55×0.50) + (7.10×0.30) + (4.65×0.20) = 7.34

---

Billing Company / DME RCM Outsourcer

Asset Sale Sub-Score:

Criterion	Wt	Score	Note
Distribution reach	30%	7	Serves 10–50 DMEPOS clients per firm
Strategic need	25%	9 (+1)	MA plan-specific PA rules are their most expensive unsolved problem
Price ceiling	20%	7 (+1)	$40K–$80K justified across 20+ clients under MA scope
Speed to close	15%	5	Owner/managing partner: 60–90 day decision cycle
Build vs. buy	10%	7	Not a tech company; will buy
Sub-score: 7.20

Pilot Sub-Score:

Criterion	Wt	Score	Note
Data accessibility	25%	10	MA + Medicaid billing data across all clients — defines the advantage
Cooperation likelihood	20%	8 (+1)	MA complexity is their daily pain; highly motivated under this payer scope
Signal quality	20%	10	Multi-supplier, multi-plan data
PHI overhead	20%	6	HIPAA infrastructure exists; BAA manageable
Feedback speed	15%	6	Fast initiation; first MA cycle data in 30 days
Sub-score: 8.20

SaaS ICP Score: 7.75 (+0.80 under MA scope — tool becomes a revenue line) Billing Company Composite: (7.20×0.50) + (8.20×0.30) + (7.75×0.20) = 7.61

---

VGM Group / MSO

Asset Sale Sub-Score:

Criterion	Wt	Score	Note
Distribution reach	30%	10	Thousands of small-to-mid DMEPOS suppliers nationally
Strategic need	25%	6 (−1)	MA/Medicaid are plan-specific problems outside VGM's policy leverage
Price ceiling	20%	7	$75K–$150K justified as member benefit
Speed to close	15%	3	6–12 month committee procurement
Build vs. buy	10%	8	VGM endorses/buys tools, does not build
Sub-score: 7.15

Pilot Sub-Score:

Criterion	Wt	Score	Note
Data accessibility	25%	3	No supplier billing data; must recruit members
Cooperation likelihood	20%	5	Conceptual support; cannot drive participation
Signal quality	20%	3 (−1)	Member base skews rural/small; less MA density
PHI overhead	20%	4	VGM as intermediary adds complexity layer
Feedback speed	15%	3	Slow: member recruitment + separate BAAs
Sub-score: 3.60

SaaS ICP Score: 5.30 VGM Composite: (7.15×0.50) + (3.60×0.30) + (5.30×0.20) = 5.72

---

Mid-Size Independent Supplier

Asset Sale Sub-Score:

Criterion	Wt	Score	Note
Distribution reach	30%	1	Single supplier; no scale
Strategic need	25%	6 (+1)	MA scope raises personal pain — daily multi-plan complexity
Price ceiling	20%	3 (+1)	MA ROI strengthens argument; still marginal for asset sale
Speed to close	15%	4	Owner decision: 2–8 weeks if motivated
Build vs. buy	10%	3	Cannot build; would subscribe not buy
Sub-score: 3.30

Pilot Sub-Score:

Criterion	Wt	Score	Note
Data accessibility	25%	7	Structured in Brightree/NikoHealth; needs 50+ MA patients for signal
Cooperation likelihood	20%	8	Billing manager engages daily; highly motivated
Signal quality	20%	7 (−2)	Thin MA mix reduces cross-plan generalizability
PHI overhead	20%	5	BAA: standard, manageable
Feedback speed	15%	8	Monthly MA billing cycle; fast iteration
Sub-score: 6.95

SaaS ICP Score: 8.10 (+0.30 — MA complexity is their most expensive unsolved problem) Mid-Size Supplier Composite: (3.30×0.50) + (6.95×0.30) + (8.10×0.20) = 5.36

---

Composite Ranking Summary (Base + MA/Medicaid Adjusted)

Rank	Segment	Base Composite	MA+Med Adj	Final Score
#1	Billing company / DME RCM	7.17	+0.44	7.61
#2	NikoHealth-type platform	7.22	+0.12	7.34
#3	VGM Group / MSO	5.98	−0.26	5.72
#4	Mid-size independent supplier	5.27	+0.09	5.36

---

The Sequencing Logic

The #1 and #2 positions are 0.27 points apart. This is not a clear winner — it is a parallel tracks signal:

1. Pilot with billing company first. 60 days. Generates denial rate reduction data from real MA + Medicaid billing. Low cost.

2. Use that evidence to close NikoHealth. The pilot data makes the NikoHealth asset sale conversation 3× easier and likely 2× more valuable in price negotiation.

These tracks are mutually reinforcing, not competing.

VGM is the correct follow-on distribution deal after the NikoHealth asset sale or billing company deployment — not the primary target during MA + Medicaid proof-of-concept.

---

MA + Medicaid: The Payer Complexity That Changes Everything

FFS Medicare: One ruleset per MAC jurisdiction (4 MACs nationally)
Medicare Advantage: 800+ plans, each with plan-specific PA rules
                    layered on top of CMS Part B baseline
Medicaid: 50 state rulesets, often MCO-layered within each state
          TRAP: Several states have moved CGM coverage to pharmacy-only
          (NY May 2024; others following) — verify before piloting

Why this matters for NikoHealth: Maintaining current MA plan-specific PA rules across 800+ plans is ongoing data work, not engineering. A supplier tool that owns this database has a moat that is expensive to replicate.

Why this matters for billing companies: They are already maintaining these rules manually in someone's spreadsheet. The pain is personal and daily.

---

Key Denial Quantification

Metric	Value	Source
CGM improper payment rate	25.2%	CMS 2024
Projected annual improper payments	$278.5M	CMS 2024
Documentation failure share	94.2%	CMS 2024
No documentation at all	67.6%	CMS 2024
Insufficient documentation	26.6%	CMS 2024
MA DMEPOS appeal success (L2)	63.9%	KFF 2024
MA PA denial rate	7.7%	KFF 2024
Write-off rate on denied claims	~63%	Derived from appeal ladder economics
Net revenue loss after appeals	~20% of gross CGM billing	Derived

---

Sources

• CMS 2024 CGM Improper Payments
• KFF: MA 53M PA Determinations 2024
• MA Denial Spike — Medicare Rights Center
• Unequal DME/Pharmacy Enforcement — CMS Comment
• UHC/Synapse Health State Expansion
• OIG CGM Payments Exceeded Costs 2025
• NY State Medicaid CGM Billing Update 2024
• NikoHealth vs Brightree 2026